Nuvectis Pharma (NVCT) Insider Trading & Ownership $4.52 -0.17 (-3.62%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Nuvectis Pharma (NASDAQ:NVCT) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage35.78%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$268,750.60Number OfInsiders Selling(Last 12 Months)0 Get NVCT Insider Trade Alerts Want to know when executives and insiders are buying or selling Nuvectis Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NVCT Insider Buying and Selling by Quarter Ad Stansberry Research2025 could be “worse than the dot-com bust”, says man who predicted 2008 banking crisisDan is sharing his latest work with the public. Because what he's tracking right now, he says, is too serious to keep private.Click here to see Dan's full warning to the public. Nuvectis Pharma Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/13/2024Marlio Charles MosseriMajor ShareholderBuy17,000$4.70$79,900.00 11/19/2024Enrique PoradosuInsiderBuy2,000$4.99$9,980.00 11/15/2024Ron BentsurCEOBuy20,000$4.92$98,400.00 5/14/2024Ron BentsurCEOBuy1,940$6.74$13,075.60 5/10/2024Enrique PoradosuInsiderBuy500$6.29$3,145.00 5/10/2024Ron BentsurCEOBuy2,000$6.40$12,800.00 3/18/2024Ron BentsurCEOBuy5,000$10.29$51,450.00 (Data available from 1/1/2013 forward) NVCT Insider Trading Activity - Frequently Asked Questions Who is on Nuvectis Pharma's Insider Roster? The list of insiders at Nuvectis Pharma includes Enrique Poradosu, Kenneth Hoberman, Marlio Charles Mosseri, Ron Bentsur, and Shay Shemesh. Learn more on insiders at NVCT. What percentage of Nuvectis Pharma stock is owned by insiders? 35.78% of Nuvectis Pharma stock is owned by insiders. Learn more on NVCT's insider holdings. Which Nuvectis Pharma insiders have been buying company stock? The following insiders have purchased NVCT shares in the last 24 months: Enrique Poradosu ($18,900.00), Marlio Charles Mosseri ($3,016,794.14), Ron Bentsur ($295,553.85), and Shay Shemesh ($12,211.50). How much insider buying is happening at Nuvectis Pharma? Insiders have purchased a total of 235,341 NVCT shares in the last 24 months for a total of $3,343,459.49 bought. Nuvectis Pharma Key ExecutivesMr. Ron Bentsur M.B.A. (Age 58)Co-Founder, Chairman, CEO & President Compensation: $1.12MDr. Enrique Poradosu Ph.D. (Age 57)Co-Founder, Executive VP, Chief Scientific & Business Officer Compensation: $705.5kMr. Shay Shemesh (Age 40)Co-Founder, Executive VP, Chief Development & Operations Officer Compensation: $705.5kMr. Michael Carson CPA (Age 48)Vice President of Finance More Insider Trading Tools from MarketBeat Related Companies NGNE Insider Selling VYGR Insider Selling DSGN Insider Selling BTMD Insider Selling SLRN Insider Selling TRVI Insider Selling CGC Insider Selling AQST Insider Selling ETON Insider Selling SAGE Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:NVCT) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NVCT Stock Alerts